Core Viewpoint - Dachen Biochemical Technology (00809) reported a revenue of HKD 2.279 billion for the year ending December 31, 2025, reflecting a year-on-year increase of 13.86%. However, net profit decreased by 79.69% to HKD 156 million, with basic earnings per share at HKD 0.014 [2]. Group 1: Financial Performance - The company achieved a revenue of HKD 2.279 billion, which is a 13.86% increase compared to the previous year [2]. - The net profit for the year was HKD 156 million, representing a significant decrease of 79.69% year-on-year [2]. - Basic earnings per share were reported at HKD 0.014 [2]. Group 2: Market Conditions and Production - The company maximized production capacity for its amino acid business, resulting in a sales volume increase of approximately 36.6% to 522,000 metric tons, compared to 382,000 metric tons in 2024 [2]. - Due to intense domestic market competition, local suppliers are shifting to sell amino acid products in the domestic market [2]. - Starting from the second half of 2025, the EU and the US will impose final anti-dumping duties on China's lysine products, leading the company to adjust its amino acid production in the fourth quarter of 2025 to achieve optimal production rates [2].

Group 1 - The company, Da Cheng Biochemical Technology, announced a proposal for a share consolidation, where every 10 existing shares with a par value of HKD 0.10 will be consolidated into 1 share with a par value of HKD 1.00 [2] - The same consolidation will apply to the existing and unissued convertible preference shares, where every 10 shares will be consolidated into 1 share with a par value of HKD 1.00 [2] - Following the consolidation, the trading unit on the Hong Kong Stock Exchange will change from 2,000 existing shares to 10,000 consolidated shares [2]

Group 1 - The company reported a revenue of HKD 2.279 billion for the year ending December 31, 2025, representing a year-on-year increase of 13.86% [1] - The net profit for the year was HKD 156 million, a significant decrease of 79.69% compared to the previous year [1] - Basic earnings per share were reported at 1.4 HK cents [1] Group 2 - The company maximized production capacity for its amino acid business, resulting in a sales volume increase of approximately 36.6% to 522,000 metric tons, up from 382,000 metric tons in 2024 [1] - Due to intense domestic market competition, local suppliers are shifting to sell amino acid products in the domestic market [1] - The company plans to adjust amino acid production in the fourth quarter of 2025 to achieve optimal production rates in response to the oversupply of amino acid products in China [1]

Core Viewpoint - Dachen Biochemical Technology (00809.HK) announced a proposal for a share consolidation, merging every ten existing shares with a par value of HKD 0.10 into one consolidated share with a par value of HKD 1.00 [1] Group 1 - The board of directors recommends the consolidation of both existing shares and convertible preference shares at the same ratio of ten to one [1] - The consolidation is subject to approval by shareholders at the annual general meeting [1] - Following the consolidation, the trading unit on the Hong Kong Stock Exchange will change from 2,000 existing shares to 10,000 consolidated shares [1]

Group 1 - The company, Da Cheng Biochemical Technology (00809), announced a proposal for a share consolidation [1] - The consolidation will involve merging every 10 existing shares with a par value of HKD 0.10 into 1 consolidated share with a par value of HKD 1.00 [1] - The same consolidation will apply to the existing convertible preference shares, where every 10 shares will be merged into 1 consolidated convertible preference share [1] Group 2 - Following the consolidation, the trading unit on the Hong Kong Stock Exchange will change from 2,000 existing shares to 10,000 consolidated shares [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 截至2025年12月31日止年度 全年業績公告 大成生化科技集團有限公司（「本公司」）董事（「董事」）會（「董事會」）公告本公司及其附屬 公司（統稱「本集團」）截至2025年12月31日止年度（「本年度」）的綜合業績連同去年的比較 數字如下： 綜合損益及其他全面收益表 截至2025年12月31日止年度 | | | 2025年 | 2024年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 收益 | 4 | 2,278,532 | 2,001,095 | | 銷售成本 | | (2,082,091) | (1,810 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 建議股份合併 董事會建議實施股份合併，基準為(i)每十(10)股每股面值0.10港元的已發行及未發行現 有股份將合併為一(1)股每股面值1.00港元的合併股份；及(ii)每十(10)股每股面值0.10港 元的已發行及未發行現有可換股優先股將合併為一(1)股每股面值1.00港元的合併可換 股優先股。股份合併須待（其中包括）股東於股東週年大會上批准後方可作實。 於本公告日期，本公司有(i)16,832,771,527股已繳足或入賬列作繳足的已發行現有股份 （包括44,560,000股庫存股份）；及(ii)17,267,750,569股已發行現有可換股優先股。股份 合併生效後並假設自本公告日期起直至 ...

Core Viewpoint - Da Cheng Biochemical Technology (00809) expects a significant decline in net income for the fiscal year ending December 31, 2025, projecting between HKD 100 million and HKD 300 million, compared to approximately HKD 746 million for the fiscal year ending December 31, 2024 [1] Financial Performance - The company anticipates revenue and gross profit to increase by approximately 13.9% and 2.8%, respectively, from about HKD 2.001 billion and HKD 191 million in the previous year to approximately HKD 2.279 billion and HKD 196 million in the current year [1] - However, the gross profit margin is expected to decline from 9.5% in the previous year to 8.6% in the current year [1] Factors Affecting Performance - The anticipated decline in gross profit margin and net income is primarily attributed to rising domestic corn prices starting mid-2025, which will increase operational costs for the company [1] - Additionally, the European Union's anti-dumping investigation into mainland China's lysine has led to an oversupply of lysine products in the domestic market, negatively impacting the company's gross profit margin [1] - The company will also not recognize a one-time gain of approximately HKD 1.962 billion following the completion of the sale of eight subsidiaries on December 30, 2024 [1]

Group 1 - The core viewpoint of the article indicates that Dachen Biochemical Technology (00809.HK) expects a significant decline in net profit for the fiscal year ending December 31, 2025, projecting a range of HKD 100 million to HKD 300 million, which is substantially lower than the approximately HKD 746 million net profit recorded for the fiscal year ending December 31, 2024 [1] Group 2 - The company has conducted a preliminary review of its unaudited consolidated management accounts for the upcoming fiscal year [1] - The expected net profit for the upcoming fiscal year represents a decrease of approximately 60% to 87% compared to the previous year's figures [1] - The announcement highlights a concerning trend in the company's financial performance, indicating potential challenges ahead [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 內幕消息 盈利警告 本公告是大成生化科技集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條以及香港法例第 571章證券及期貨條例第XIVA部項下的內幕消息條文而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及本公司潛在投資者， 根據對現時可得的本集團截至二零二五年十二月三十一日止年度（「本年度」）未經審核綜 合管理賬目所作出的初步審閱，本集團預期將於本年度錄得淨收益（扣除稅項影響前）， 範圍約在100,000,000港元至300,000,000港元，遠低於本集團截至二零二四年十二月三十 一日止年度（「去 ...